- Home
- CLGN
as 12-18-2024 3:33pm EST
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
| Founded: | 2004 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 51.3M | IPO Year: | N/A |
| Target Price: | $12.50 | AVG Volume (30 days): | 13.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.31 - $6.99 | Next Earning Date: | 11-27-2024 |
| Revenue: | $650,000 | Revenue Growth: | -93.94% |
| Revenue Growth (this year): | -84.73% | Revenue Growth (next year): | 692.59% |
Latest CollPlant Biotechnologies Ltd News
CLGN Breaking Stock News: Dive into CLGN Ticker-Specific Updates for Smart Investing
PR Newswire
21 days ago
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
GuruFocus.com
22 days ago
What To Expect From CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings
Simply Wall St.
a month ago
US Penny Stocks With Market Caps Under $3B
PR Newswire
a month ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
Simply Wall St.
a month ago
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In Growth
Simply Wall St.
4 months ago
Even after rising 10% this past week, CollPlant Biotechnologies (NASDAQ:CLGN) shareholders are still down 71% over the past three years
PR Newswire
4 months ago
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
PR Newswire
4 months ago
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
Compare CLGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLGN CollPlant Biotechnologies Ltd - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.